Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Has High Hopes For Tasigna And Predicts It Could Outpace Gleevec In CML

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis execs are "pleased" with Tasigna's safety profile in a head-to-head study against the more lucrative CML therapy, Gleevec.

You may also be interested in...



Gleevec Extends Post-Surgery GIST Survival Significantly; Wins Full Adjuvant Approval

Patients who took Novartis’ Gleevec for three years after surgery to remove gastrointestinal stromal tumors had a 54% reduction in risk of recurrence and a 55% reduction in risk of death compared to patients who took it for only one year.

Beyond Gleevec: What's Next For Novartis Oncology?

For Novartis, the targeted chronic myeloid leukemia drug Gleevec (imatinib) has been the backbone of its oncology portfolio. The drug's launch in 2003 catapulted Novartis into a major oncology player, and with revenues for Gleevec now approaching close to $4 billion in sales annually, the drug has evolved from what was considered to be a niche treatment into Novartis' second top-selling drug

Beyond Gleevec: What's Next For Novartis Oncology?

For Novartis, the targeted chronic myeloid leukemia drug Gleevec (imatinib) has been the backbone of its oncology portfolio. The drug's launch in 2003 catapulted Novartis into a major oncology player, and with revenues for Gleevec now approaching close to $4 billion in sales annually, the drug has evolved from what was considered to be a niche treatment into Novartis' second top-selling drug

Related Content

Topics

UsernamePublicRestriction

Register

PS068646

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel